Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.
Marion T van MackelenberghSibylle LoiblMichael UntchMarc E BuyseCharles E GeyerLuca GianniAndreas SchneeweißPierFranco ConteMartine J PiccartHervé R BonnefoiChristian JackischValentina NekljudovaGong TangPinuccia ValagussaColin NeateRichard D GelberCoralie PoncetPierre SquiffletEverardo Delforge SaadDominik HeinzmannCarsten DenkertPriya RastogiJavier CortesValentina GuarneriEvandro de AzambujaDavid A CameronGustavo IsmaelNorman WolmarkPatricia CortazarPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
These results confirm that patients achieving pCR have far better survival outcomes than patients who do not. The traditional poor prognostic features, namely tumor size and nodal status, remain important even after a pCR.
Keyphrases
- epidermal growth factor receptor
- neoadjuvant chemotherapy
- tyrosine kinase
- advanced non small cell lung cancer
- endothelial cells
- locally advanced
- lymph node
- early breast cancer
- sentinel lymph node
- end stage renal disease
- newly diagnosed
- ejection fraction
- induced pluripotent stem cells
- peritoneal dialysis
- case report
- radiation therapy
- early stage
- cell therapy